Printer Friendly

BIOPOOL TEST KIT POINTS TO t-PA AS INDICATOR FOR HEART ATTACK RISK; HARVARD STUDY PUBLISHED IN LANCET

 VENTURA, Calif., May 10 /PRNewswire/ -- Biopool International Inc. (NASDAQ: BIPL) today announced the results of a Harvard Medical School study demonstrating that plasma levels of tissue-type plasminogen activator (t-PA) may be an even more important indicator of risk for future heart attack than cholesterol. Clinical investigators used Biopool's TintElize(R) t-PA test kit to measure the plasma levels in the two patient groups. These results were recently published in Lancet, a highly regarded medical journal.
 The study's principal investigator, Dr. Paul Ridker of Brigham and Women's Hospital and Harvard Medical School, analyzed plasma samples from subjects in the Physicians' Health Study. The study consisted of 231 apparently healthy men who later developed myocardial infarction and a control group of 231 men, matched for age and smoking habits, who remained free of cardiovascular disease during the follow-up period of over five years. Individuals with t-PA levels in the top 20 percent were three times more likely to have a heart attack as individuals who had t-PA levels in the bottom 20 percent, according to the data.
 "These results suggest that elevated plasma t-PA antigen may be a marker of pre-clinical atherosclerosis among asymptomatic men. In this group of healthy men t-PA appears to be a stronger indicator of heart attack risk than total cholesterol," said Ridker. "The prospective design of this study rules out the possibility that the increased t-PA levels are a consequence of infarction and dramatically reduces bias in the selection of the control group."
 "The extraordinary results of this study published in Lancet should most certainly increase worldwide interest in the use of Biopool's TentElize t-PA test kit," said Andrew L. Cerskus, president and chief operating officer. "We are pleased that our test kit was chosen for use in this important study, and that the medical community has recognized Biopool's reputation as a pioneer in the clinical testing of t-PA."
 Founded in 1987, Biopool develops, manufactures and markets a full range of test kits to assess and diagnose disorders of blood coagulation, fibrinolysis, platelet function and the vascular system, as well as test kits to determine thrombotic risk factors. The company's products are sold to hospitals and clinical laboratories worldwide.
 -0- 5/10/93
 /CONTACT: Andrew L. Cerskus, Ph.D., president and COO of Biopool, 416-332-9419; or Kim P. Feazle of Pondel Parsons & Wilkinson, 310-207-9300, for Biopool/
 (BIPL)


CO: Biopool International Inc. ST: California IN: HEA SU: PDT

LS-JL -- LA012 -- 6319 05/10/93 09:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 10, 1993
Words:409
Previous Article:ALLIED HEALTHCARE PRODUCTS INC. ANNOUNCES THIRD QUARTER DIVIDEND DECLARATION
Next Article:ESCAGENETICS RECEIVES SUPPLEMENT FUNDING FROM NATIONAL CANCER INSTITUTE FOR PLANT CELL TISSUE CULTURE TAXOL
Topics:


Related Articles
BIOPOOL PRESENTS PAPER AT INTERNATIONAL FIBRINOLYSIS CONFERENCE
BIOPOOL RECEIVES FDA APPROVAL TO MARKET MINUTEX(TM) D-DIMER AND SPECTROLYSE PL/PAI TEST KITS
BIOPOOL REPORTS FIRST QUARTER RESULTS AND FIFTH CONSECUTIVE PROFITABLE QUARTER
BIOPOOL COMPLETES FINANCING
BIOPOOL NAMES DOUGLAS L. AYER TO BOARD OF DIRECTORS
BIOPOOL RECEIVES FDA 510(k) APPROVAL FOR t-PA TEST KITS; t-PA STUDY PUBLISHED IN LANCET
BIOPOOL REPORTS FIRST QUARTER RESULTS; EARNINGS UP THREEFOLD
BIOPOOL TEST KIT LINKS ALCOHOL USE TO REDUCED RISK OF HEART ATTACK
BIOPOOL INTERNATIONAL RECEIVES FDA APPROVAL TO MARKET FIVE (5) NEW CHEMISTRY REAGENT SYSTEMS
BIOPOOL INTERNATIONAL ACQUIRES NEW TECHNOLOGY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters